(S)-1-acetyl-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)piperidine-4-carboxamide | 1620068-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-1-acetyl-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)piperidine-4-carboxamide
• 英文别名: 1-acetyl-N-[3-[[1-[2-[[(2S)-2-hydroxypropyl]amino]pyrimidin-4-yl]imidazol-2-yl]methyl]phenyl]piperidine-4-carboxamide
• CAS: 1620068-94-1
• 化学式: C₂₅H₃₁N₇O₃
• 分子量: 477.566
• InChiKey: QKSPPYKJDJMPFH-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-硝基苯乙腈 在 盐酸 、 potassium phosphate 、 氢气 、 palladium diacetate 、 1-羟基苯并三唑 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 16.0h， 生成 (S)-1-acetyl-N-(3-((1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazol-2-yl)methyl)phenyl)piperidine-4-carboxamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors

  摘要：

  The synthesis of a novel series of (4-aminobenzyl/benzoyl)-1H-imidazol-1-yl pyrimidin-2-yl derivatives 9, 10, 18, 19 and their in vitro antiproliferative activities against the A375P human melanoma cell line and the U937 human leukemic monocyte lymphoma cell line are described. Potent antiproliferative effects were found from 91, 9s and 10c; 10c was found to be a highly potent and selective BRAF V600E and CRAF inhibitor (IC50 = 38.3 nM and 8.79 nM). (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.030

文献信息

• Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient
  申请人：Industry-University Cooperation Foundation Hanyang University ERICA Campus

  公开号：US20160200706A1

  公开（公告）日：2016-07-14

  The present invention relates to a novel imidazole-1-yl pyrimidine derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutic composition comprising the same. Since the imidazole-1-yl pyrimidine derivative according to the present invention shows the inhibition activity selectively to BRAF, BRAF mutants, or CRAF, it can be used to a pharmaceutic composition for preventing or treating cancer.

  本发明涉及一种新型咪唑-1-基嘧啶衍生物，其药用盐以及包含该衍生物的药物组合物。由于根据本发明，咪唑-1-基嘧啶衍生物显示出对BRAF、BRAF突变体或CRAF的选择性抑制活性，因此可用于预防或治疗癌症的药物组合物。
• US9540348B2
  申请人：——

  公开号：US9540348B2

  公开（公告）日：2017-01-10
• Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors
  作者：Minjung Kim、Junghun Lee、Kyungjin Jung、Hyangmi Kim、Waqar Aman、Jae-Sang Ryu、Jung-Mi Hah

  DOI：10.1016/j.bmcl.2014.05.030

  日期：2014.8

  The synthesis of a novel series of (4-aminobenzyl/benzoyl)-1H-imidazol-1-yl pyrimidin-2-yl derivatives 9, 10, 18, 19 and their in vitro antiproliferative activities against the A375P human melanoma cell line and the U937 human leukemic monocyte lymphoma cell line are described. Potent antiproliferative effects were found from 91, 9s and 10c; 10c was found to be a highly potent and selective BRAF V600E and CRAF inhibitor (IC50 = 38.3 nM and 8.79 nM). (C) 2014 Elsevier Ltd. All rights reserved.